The EPS miss is mechanical from clinical ramp-up spending and does not signal fundamental weakness. The key catalyst is mid-2026 site activations for the EB06 vitiligo Phase 2 trial — monitor for regulatory clearance and enrollment updates. Cash runway of ~$10M provides roughly 12-15 months at current burn rate, suggesting a potential capital raise before year-end if no non-dilutive funding materializes.
Price Chart
Executive Summary
Edesa Biotech reported Q2 2026 net loss of $4.2M ($0.49/share), wider than the $1.6M loss ($0.30/share) a year ago, as R&D spending surged 5.7x to $2.8M to prepare for a Phase 2 vitiligo study of EB06. The EPS of -$0.49 missed the consensus estimate of -$0.26 by 88.5%, but the company has no revenue and the miss is driven by planned clinical ramp-up spending, not operational deterioration. Management reaffirmed mid-2026 site activations for the vitiligo trial and highlighted consistent Phase 3 ARDS data for paridiprubart across patient subgroups.
Key Financial Metrics
Key Facts
- Q2 2026 net loss of $4.2M vs $1.6M in Q2 2025; EPS -$0.49 vs -$0.30
- R&D expenses increased $2.3M to $2.8M, driven by EB06 vitiligo trial prep and paridiprubart manufacturing readiness
- Cash and equivalents at $10.0M, down from $10.8M at Sept 30, 2025
- Management reaffirmed guidance: site activations and patient recruitment for EB06 Phase 2 vitiligo study expected to begin mid-2026
- Additional positive Phase 3 data for paridiprubart in ARDS showed consistent benefits across disease severity and comorbidity subgroups
- EPS of -$0.49 missed consensus of -$0.26 by 88.5%, but the miss is driven by planned clinical spending, not business deterioration
Financial Impact
Net loss widened by $2.6M YoY; cash burn of $0.8M in H1 2026; no revenue generated
Risk Factors
- Cash runway of $10M may require additional financing within 12 months if operating expenses continue to rise
- Phase 2 vitiligo trial subject to regulatory approval — delays could push timeline
- No approved products or revenue; stock price highly sensitive to clinical data readouts and financing events
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295422 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K | $2.59 | awaiting T+20 | — | $2.63 (+1.54%) |
Oct 15, 2026 12d ago | 8-K | $2.67 | awaiting T+20 | — | $2.63 (−1.50%) |
Oct 15, 2026 12d ago | Press Release | $2.67 | awaiting T+20 | — | $2.63 (−1.50%) |
Aug 19, 2026 9w ago | Press Release | $4.76 $4.14 | ▲ +13.03% | ▲ +13.03% | $2.63 (+44.75%) |
Jul 14, 2026 15w ago | EFFECT | $6.74 $5.52 | ▲ +18.10% | ▲ +20.59% | $2.63 (+60.98%) |
Jul 2, 2026 16w ago | S-3 | $7.50 $5.25 | ▼ −30.00% | ▼ −29.59% | $2.63 (−64.93%) |
Jun 5, 2026 20w ago | 8-K | $5.46 $7.21 | ▲ +32.05% | ▲ +30.19% | $2.63 (−51.83%) |
Jun 5, 2026 20w ago | Press Release | $5.46 $7.21 | ▲ +32.05% | ▲ +30.19% | $2.63 (−51.83%) |
May 29, 2026 21w ago | 8-K | $6.69 $8.13 | ▲ +21.52% | ▲ +22.82% | $2.63 (−60.69%) |
May 19, 2026 23w ago | Press Release | $11.95 $6.88 | ▼ −42.43% | ▼ −43.41% | $2.63 (−77.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers